1056. Influence of Parity and Sexual History on Cytomegalovirus Seroprevalence among Women 20-49 Years-old
Session: Poster Abstract Session: Herpesviruses, HPV, and Other Viruses
Friday, October 9, 2015
Room: Poster Hall
Posters
  • Lanzieri_CMV seroprevalence_IDweek2015--001_r.pdf (123.3 kB)
  • Background: Among women of reproductive age, exposure to cytomegalovirus (CMV) can occur through contact with children with CMV infection or through sexual contact. We assessed the influence of parity, as a proxy for exposure to children, and sexual history on CMV seroprevalence among women 20-49 years-old in the United States.

    Methods: We analyzed data from the 1999-2004 National Health and Nutrition Examination Survey using logistic regression to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI).

    Results: Women who had given birth to ≥1 child had a higher overall age-adjusted seroprevalence (66.0%; 95% CI: 63.1-68.9%) compared to those who had not (49.0%; 95% CI: 44.4-53.7%) (p<0.001). Higher CMV seroprevalence was independently associated with increasing number of live births (aOR=1.2, 95%CI=1.1-1.3, for each additional live birth), age at first sexual intercourse <18 years vs. ≥ 18 (aOR=1.3, 95%CI=1.1-1.6), number of life time sexual partners ≥10 vs. <10 (aOR=1.4, 95%CI=1.1-1.9), and herpes type II positivity (aOR=1.9, 95%CI=1.5-2.6) after controlling for age group, race/Hispanic origin, place of birth, poverty index ratio, and education level (p<0.05).  

    Conclusion: Having previous live births was independently associated with higher CMV seroprevalence, after adjustment for sociodemographic factors and sexual history. Although it is difficult to determine the relative contribution of contact with young children as opposed to sexual contact to CMV seroprevalence, population-based data are consistent with contact with children being a source of infection for women of reproductive age.

    Tatiana M. Lanzieri, MD, MPH1, Deanna Kruszon-Moran, MS2 and Stephanie R. Bialek, MD, MPH1, (1)National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (2)National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD

    Disclosures:

    T. M. Lanzieri, None

    D. Kruszon-Moran, None

    S. R. Bialek, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.